MAZE

Maze Therapeutics

• Seeking Alpha·1d ago

  Maze Therapeutics: Intriguing Kidney Disease Assets Put This On The Watchlist

• TipRanks·08/17 20:51

  Maze Therapeutics Strengthens Board with New Director Appointments

• Dow Jones·08/13 20:43

  *Maze Therapeutics Names Paula Johnson and Sophie Kornowski to Its Bd >MAZE

• Dow Jones·08/13 20:42

  Press Release: Maze Therapeutics Announces Appointments to Its Board of Directors

• TipRanks·08/13 11:57

  Truist Financial Reaffirms Their Buy Rating on Maze Therapeutics, Inc. (MAZE)

• TipRanks·08/13 06:00

  Legal and Regulatory Risks Threaten Maze Therapeutics’ Funding, Reputation and Path to Commercialization

• NASDAQ·08/12 15:22

  Maze Posts Wider Loss In Q2; Expects Phase 2 CIPheR Data For MZE782 In FY27

• TipRanks·08/12 12:30

  Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT)

• TipRanks·08/12 11:40

  Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Maze Therapeutics, Inc. (MAZE) and Immunome (IMNM)

• TipRanks·08/12 11:00

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (ENGN) and Maze Therapeutics, Inc. (MAZE)

• TipRanks·08/12 10:36

  Maze Therapeutics: Buy Rating Reaffirmed as Clinical De-Risking Supports Unchanged $110 Price Target

• TipRanks·08/12 10:25

  Maze Therapeutics: Buy Rating Reiterated on Strong Cash Runway and Advancing APOL1/PKU Programs; Price Target Maintained at $57

• Benzinga·08/12 10:00

  BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target

• Dow Jones·08/11 20:02

  *Maze Therapeutics: Expected Runway Into 2029 >MAZE

• TipRanks·07/14 16:31

  Maze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE Investors